Downregulation of thymopoietin by miR‑139‑5p suppresses cell proliferation and induces cell cycle arrest/apoptosis in pancreatic ductal adenocarcinoma

Zhou,Huadong; Zhang,Linfei; Tu,Huahua

doi:10.3892/ol.2019.10679

Downregulation of thymopoietin by miR‑139‑5p suppresses cell proliferation and induces cell cycle arrest/apoptosis in pancreatic ductal adenocarcinoma

Authors:
- Huadong Zhou
- Linfei Zhang
- Huahua Tu
View Affiliations

Affiliations: Department of Hepatobiliary Pancreatic Surgery, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China
Published online on: July 29, 2019 https://doi.org/10.3892/ol.2019.10679
Pages: 3443-3452
Copyright: © Zhou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs (miRNAs) serve a pivotal role in tumor development and progression, in which miRNA (miR)‑139‑5p functions as a tumor suppressor. However, the functions and mechanisms of miR‑139‑5p in pancreatic ductal adenocarcinoma (PDAC) remain unclear. In the present study, it was found that miR‑139‑5p was markedly decreased in PDAC tissues and cell lines. Noticeably, thymopoietin (TMPO) was predicted and confirmed as a direct target of miR‑139‑5p using a luciferase reporter system. The expression level of miR‑139‑5p was inversely associated with the expression of TMPO in PDAC specimens. A series of gain‑of‑function assays elucidated that the overexpression of miR‑139‑5p suppressed cell proliferation, and induced cell cycle arrest and cell apoptosis, determined with a Cell Counting Kit‑8, colony formation assays and flow cytometry, respectively. Furthermore, the re‑expression of TMPO eliminated the effects of miR‑139‑5p on cell proliferation, cell cycle progression and apoptosis. In summary, these findings demonstrated that miR‑139‑5p may be a tumor suppressor in PDAC, which may be useful in developing promising therapies for PDAC.

View Figures

View References

1	Sahakyan MA, Kim SC, Kleive D, Kazaryan AM, Song KB, Ignjatovic D, Buanes T, Røsok BI, Labori KJ and Edwin B: Laparoscopic distal pancreatectomy for pancreatic ductal adenocarcinoma: Long-term oncologic outcomes after standard resection. Surgery. 162:802–811. 2017. View Article : Google Scholar : PubMed/NCBI
2	Hwang CI, Boj SF, Clevers H and Tuveson DA: Preclinical models of pancreatic ductal adenocarcinoma. J Pathol. 238:197–204. 2016. View Article : Google Scholar : PubMed/NCBI
3	Dunne RF and Hezel AF: Genetics and biology of pancreatic ductal adenocarcinoma. Hematol Oncol Clin North Am. 29:595–608. 2015. View Article : Google Scholar : PubMed/NCBI
4	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
5	Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM and Matrisian LM: Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 74:2913–2921. 2014. View Article : Google Scholar : PubMed/NCBI
6	Moffitt RA, Marayati R, Flate EL, Volmar KE, Loeza SG, Hoadley KA, Rashid NU, Williams LA, Eaton SC, Chung AH, et al: Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet. 47:1168–1178. 2015. View Article : Google Scholar : PubMed/NCBI
7	Delpu Y, Hanoun N, Lulka H, Sicard F, Selves J, Buscail L, Torrisani J and Cordelier P: Genetic and epigenetic alterations in pancreatic carcinogenesis. Curr Genomics. 12:15–24. 2011. View Article : Google Scholar : PubMed/NCBI
8	Imaoka H, Toiyama Y, Okigami M, Yasuda H, Saigusa S, Ohi M, Tanaka K, Inoue Y, Mohri Y and Kusunoki M: Circulating microRNA-203 predicts metastases, early recurrence, and poor prognosis in human gastric cancer. Gastric Cancer. 19:744–753. 2016. View Article : Google Scholar : PubMed/NCBI
9	Acunzo M, Romano G, Wernicke D and Croce CM: MicroRNA and cancer-a brief overview. Adv Biol Regul. 57:1–9. 2015. View Article : Google Scholar : PubMed/NCBI
10	Catalanotto C, Cogoni C and Zardo G: MicroRNA in control of gene expression: An overview of nuclear functions. Int J Mol Sci. 17:E17122016. View Article : Google Scholar : PubMed/NCBI
11	Tüfekci KU, Meuwissen RL and Genç S: The role of microRNAs in biological processes. Methods Mol Biol. 1107:15–31. 2014. View Article : Google Scholar : PubMed/NCBI
12	Zhang HD, Jiang LH, Sun DW, Li J and Tang JH: MiR-139-5p: Promising biomarker for cancer. Tumour Biol. 36:1355–1365. 2015. View Article : Google Scholar : PubMed/NCBI
13	Yonemori M, Seki N, Yoshino H, Matsushita R, Miyamoto K, Nakagawa M and Enokida H: Dual tumor-suppressors miR-139-5p and miR-139-3p targeting matrix metalloprotease 11 in bladder cancer. Cancer Sci. 107:1233–1242. 2016. View Article : Google Scholar : PubMed/NCBI
14	Sun C, Sang M, Li S, Sun X, Yang C, Xi Y, Wang L, Zhang F, Bi Y, Fu Y and Li D: Hsa-miR-139-5p inhibits proliferation and causes apoptosis associated with down-regulation of c-Met. Oncotarget. 6:39756–39792. 2015. View Article : Google Scholar : PubMed/NCBI
15	Hua S, Lei L, Deng L, Weng X, Liu C, Qi X, Wang S, Zhang D, Zou X, Cao C, et al: miR-139-5p inhibits aerobic glycolysis, cell proliferation, migration, and invasion in hepatocellular carcinoma via a reciprocal regulatory interaction with ETS1. Oncogene. 37:1624–1636. 2018. View Article : Google Scholar : PubMed/NCBI
16	Li Q, Liang X, Wang Y, Meng X, Xu Y, Cai S, Wang Z, Liu J and Cai G: miR-139-5p inhibits the epithelial-mesenchymal transition and enhances the chemotherapeutic sensitivity of colorectal cancer cells by downregulating BCL2. Sci Rep. 6:271572016. View Article : Google Scholar : PubMed/NCBI
17	Agosta C, Laugier J, Guyon L, Denis J, Bertherat J, Libé R, Boisson B, Sturm N, Feige JJ, Chabre O and Cherradi N: MiR-483-5p and miR-139-5p promote aggressiveness by targeting N-myc downstream-regulated gene family members in adrenocortical cancer. Int J Cancer. 143:944–957. 2018. View Article : Google Scholar : PubMed/NCBI
18	Li J, Su L, Gong YY, Ding ML, Hong SB, Yu S and Xiao HP: Downregulation of miR-139-5p contributes to the antiapoptotic effect of liraglutide on the diabetic rat pancreas and INS-1 cells by targeting IRS1. PLoS One. 12:e01735762017. View Article : Google Scholar : PubMed/NCBI
19	Marrero-Rodríguez D, Taniguchi-Ponciano K, Lopez-Sleman J, Romero-Morelos P, Mendoza-Rodríguez M, Garcia I, Huerta-Padilla V, Mantilla A, Duarte A, Piña P, et al: Thymopoietin beta and gamma isoforms as a potential diagnostic molecular marker for breast cancer: Preliminary data. Pathol Oncol Res. 21:1045–1050. 2015. View Article : Google Scholar : PubMed/NCBI
20	Gesson K, Vidak S and Foisner R: Lamina-associated polypeptide (LAP)2α and nucleoplasmic lamins in adult stem cell regulation and disease. Semin Cell Dev Biol. 29:116–124. 2014. View Article : Google Scholar : PubMed/NCBI
21	Dechat T, Vlcek S and Foisner R: Review: Lamina-associated polypeptide 2 isoforms and related proteins in cell cycle-dependent nuclear structure dynamics. J Struct Biol. 129:335–345. 2000. View Article : Google Scholar : PubMed/NCBI
22	Zhang L, Wang G, Chen S, Ding J, Ju S, Cao H and Tian H: Depletion of thymopoietin inhibits proliferation and induces cell cycle arrest/apoptosis in glioblastoma cells. World J Surg Oncol. 14:2672016. View Article : Google Scholar : PubMed/NCBI
23	Kim HJ, Hwang SH, Han ME, Baek S, Sim HE, Yoon S, Baek SY, Kim BS, Kim JH, Kim SY and Oh SO: LAP2 is widely overexpressed in diverse digestive tract cancers and regulates motility of cancer cells. PLoS One. 7:e394822012. View Article : Google Scholar : PubMed/NCBI
24	Jung H, Lee HH, Song KY, Jeon HM and Park CH: Validation of the seventh edition of the American Joint Committee on Cancer TNM staging system for gastric cancer. Cancer. 117:2371–2378. 2011. View Article : Google Scholar : PubMed/NCBI
25	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
26	Ferreira HJ and Esteller M: Non-coding RNAs, epigenetics, and cancer: Tying it all together. Cancer Metastasis Rev. 37:55–73. 2018. View Article : Google Scholar : PubMed/NCBI
27	Yan H, Bonasio R, Simola DF, Liebig J, Berger SL and Reinberg D: DNA methylation in social insects: How epigenetics can control behavior and longevity. Annu Rev Entomol. 60:435–452. 2015. View Article : Google Scholar : PubMed/NCBI
28	Piletič K and Kunej T: MicroRNA epigenetic signatures in human disease. Arch Toxicol. 90:2405–2419. 2016. View Article : Google Scholar : PubMed/NCBI
29	Miyoshi J, Toden S, Yoshida K, Toiyama Y, Alberts SR, Kusunoki M, Sinicrope FA and Goel A: MiR-139-5p as a novel serum biomarker for recurrence and metastasis in colorectal cancer. Sci Rep. 7:433932017. View Article : Google Scholar : PubMed/NCBI
30	Furukawa K: LAP2 binding protein 1 (L2BP1/BAF) is a candidate mediator of LAP2-chromatin interaction. J Cell Sci. 112:2485–2492. 1999.PubMed/NCBI
31	Gant TM, Harris CA and Wilson KL: Roles of LAP2 proteins in nuclear assembly and DNA replication: Truncated LAP2beta proteins alter lamina assembly, envelope formation, nuclear size, and DNA replication efficiency in Xenopus laevis extracts. J Cell Biol. 144:1083–1096. 1999. View Article : Google Scholar : PubMed/NCBI
32	Dorner D, Vlcek S, Foeger N, Gajewski A, Makolm C, Gotzmann J, Hutchison CJ and Foisner R: Lamina-associated polypeptide 2alpha regulates cell cycle progression and differentiation via the retinoblastoma-E2F pathway. J Cell Biol. 173:83–93. 2006. View Article : Google Scholar : PubMed/NCBI